WP
TCRX icon

Woodline Partners’s TScan Therapeutics TCRX Stock Holding History

Woodline Partners’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-115,866
Closed -$352K – 1028
2024
Q4 		$352K Buy
115,866
+7,282
+7% +$33K ﹤0.01% 874
2024
Q3 		$541K Sell
108,584
-54,908
-34% -$331K ﹤0.01% 533
2024
Q2 		$956K Buy
+163,492
New +$1.29M 0.01% 464
2022
Q4 		– Sell
-66,601
Closed -$203K – 842
2022
Q3 		$203K Sell
66,601
-65,716
-50% -$215K ﹤0.01% 650
2022
Q2 		$416K Sell
132,317
-4,613
-3% -$12.6K 0.01% 582
2022
Q1 		$383K Buy
136,930
+37,030
+37% +$160K 0.01% 525
2021
Q4 		$450K Buy
+99,900
New +$721K 0.01% 559

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
CC
Checkpoint Capital San Francisco, California $279M AUM 45.74% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Woodline Partners's TCRX Position: Q1 2025 in Review

Woodline Partners sold out of TScan Therapeutics (TCRX) in Q1 2025, closing a stake of 115,866 shares — an estimated $352K sold.

Woodline Partners first reported a position in TCRX in Q4 2021 and held it in 7 quarters. The position peaked at $956K in Q2 2024. 92 funds tracked by Wall St. Rank hold TCRX as of Q1 2025.

  • Woodline Partners reported no remaining TScan Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Woodline Partners sold 115,866 TScan Therapeutics shares in Q1 2025, an estimated $352K.
  • Woodline Partners first reported a position in TScan Therapeutics in Q4 2021 and held it in 7 quarters.
  • Woodline Partners's TScan Therapeutics position peaked at $956K in Q2 2024.
  • 92 funds tracked by Wall St. Rank held TScan Therapeutics as of Q1 2025.

Based on Woodline Partners's 13F filing for Q1 2025, filed 15 May 2025.